A global, multicenter, open-label, randomized, Phase 3 registration study evaluating olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia (POLARIS-2).

Principal Investigator

Dott.ssa Elena Crisà

Contact Information for Access

Phase

FASE III

Status

ATTIVO

---

Objective of the study

The purpose of the study is to evaluate the superior efficacy of treatment with Olverembatinib compared to the standard therapy, Bosutinib.

Myeloid leukemia

ClinicalTrials.gov ID NCT06423911
Sponsor: Ascentage Pharma Group Inc.

Pathologies

Onco-hematological (hematological cancers/malignancies)

Medication

Olverembatinib vs. Bosutinib

Who is eligible to participate in the study?

Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with chronic-phase chronic myeloid leukemia who have been treated with at least two TKIs.

View the full study Back to search page